Shots:

• InveniAI is eligible to receive up to $200M/ program as up front- development- and commercial milestones along with royalties
• The collaboration integrates InveniAI's AI platform AlphaMeld to identify- evaluate- optimize novel targets with Shionogi's expertise in developing and commercializing therapeutic modalities
• Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will be responsible for developing- manufacturing- and commercializing the candidates

  Ref: GlobeNewswire | Image: Pharma Boardroom